| Document Date: 2014-05-13 13:28:54
Open Document File Size: 2,26 MBShare Result on Facebook
Company Diagnostic / GU Oncology Program / / Facility Texas Texas AM HSC College of Medicine US Oncology Predictive / PA Baylor-Sammons Cancer Center / Memorial Sloan-Kettering Cancer Center / / IndustryTerm cancer management / / MedicalCondition dyslipidemia mTOR Inhibitor Candidates / tumor / Congestive heart failure / cancer / Poorer risk disease / likely clinical disease / metastatic renal cell carcinoma / Refractory diabetes / progressive disease / metastases / tumour / / Organization Texas Texas AM HSC College of Medicine US Oncology Predictive / Memorial Sloan-Kettering Cancer Center / PA Baylor-Sammons Cancer Center Dallas / / Person Thomas E Hutson / DO / / Position Excellence Co-Chair / GU Research Texas Oncology / Co-Director / Professor of Medicine Director / / RadioStation Texas Texas AM / /
SocialTag |
Who is the ideal mTOR patient ? Thomas E Hutson, DO, PharmD, FACP Professor of Medicine Director, GU Oncology Program Co-Director, GU Center of Excellence